All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
Tesamorelin (GHRH analog)
For educational and research purposes only. Not medical advice.
Tesamorelin is FDA-approved and has robust evidence for visceral fat reduction. Clinical trials demonstrated 15-18% reduction in visceral adipose tissue. Also shows cognitive benefits in studies of aging populations.
Best Time
Before bed or morning, fasted
Method
subcutaneous
Frequency
Daily
Half-life
26 minutes (but GH release lasts hours)
Cycle Length
26 weeks per FDA protocol
Storage
Refrigerate at 2-8°C. Reconstitute fresh.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 54 (11) :1642-51 · 2012-06-01
Obesity research & clinical practice 20 (1) :2-12 · 2026-01-01
AIDS (London, England) 31 (16) :2253-2259 · 2017-10-23
Journal of acquired immune deficiency syndromes (1999) 53 (3) :311-22 · 2010-03-01
The Journal of clinical endocrinology and metabolism 97 (12) :4769-79 · 2012-12-01
Mechanism of Action
Synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to produce and release GH. Specifically targets visceral adipose tissue reduction.
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.